Aptus Capital Advisors LLC Acquires 5,248 Shares of Stryker Corporation $SYK

Key Points

• Aptus Capital Advisors LLC increased its stake in Stryker by 4.9%, buying an additional 5,248 shares to hold 112,736 shares worth about $41.675 million at the end of the quarter.
• Stryker beat expectations for the quarter with EPS of $4.47 vs. $4.40 and revenue of $7.17 billion (up 11.4% year-over-year), and analysts maintain a "Moderate Buy" consensus with an average target of $428.61 and a projected full-year EPS of 13.47.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.73 million, cutting her holding by about 9.23%, while insiders collectively own 5.90% of the company.

Aptus Capital Advisors LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 4.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,736 shares of the medical technology company's stock after purchasing an additional 5,248 shares during the quarter. Aptus Capital Advisors LLC's holdings in Stryker were worth $41,675,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Clayton Financial Group LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC bought a new stake in Stryker in the 2nd quarter valued at $28,000. Kilter Group LLC purchased a new stake in Stryker in the 2nd quarter worth $29,000. Howard Hughes Medical Institute bought a new position in shares of Stryker during the 2nd quarter valued at about $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker during the third quarter valued at about $34,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of NYSE:SYK opened at $370.07 on Friday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The company has a market capitalization of $141.62 billion, a price-to-earnings ratio of 44.06, a PEG ratio of 2.23 and a beta of 0.85. The firm's 50-day moving average is $365.25 and its 200 day moving average is $369.27.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm's quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $4.01 earnings per share. Research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is presently 41.90%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. The Goldman Sachs Group set a $399.00 target price on Stryker in a research report on Friday, January 9th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday. Piper Sandler reiterated an "overweight" rating on shares of Stryker in a research report on Tuesday, January 27th. Sanford C. Bernstein boosted their price target on shares of Stryker from $450.00 to $465.00 and gave the stock an "outperform" rating in a research report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Stryker in a research note on Monday, December 22nd. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $428.61.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.